APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide-based Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Peptide-based Drug Market Analysis and Forecast 2026-2032

2 January 2026199 pages

Choose your research edition.

Industry ResearchPeptide-based Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide-based Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Peptide-based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide-based Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide-based Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Peptide-based Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Peptide-based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Peptide-based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Peptide-based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Peptide-based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Peptide-based Drug include Takeda, Teva, Sanofi, J & J, Novartis, Merck, Eli Lilly, AbbVie and AstraZeneca, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Peptide-based Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peptide-based Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Peptide-based Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide-based Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peptide-based Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Peptide-based Drug revenue, projected growth trends, production technology, application and end-user industry.

Peptide-based Drug Segment by Company

Takeda

Teva

Sanofi

J & J

Novartis

Merck

Eli Lilly

AbbVie

AstraZeneca

The Medicines

Novo Nordisk

Ipsen

Ferring

Peptide-based Drug Segment by Type

Injection

Oral

Other

Peptide-based Drug Segment by Application

Cancer

Metabolic Disorders

Central Nervous System

Other

Peptide-based Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Peptide-based Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Peptide-based Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide-based Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptide-based Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Injection Major Player Table 3. Oral Major Player Table 4. Other Major Player Table 5. Global Peptide-based Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Cancer Major Player Table 7. Metabolic Disorders Major Player Table 8. Central Nervous System Major Player Table 9. Other Major Player Table 10. Peptide-based Drug Industry Trends Table 11. Peptide-based Drug Industry Drivers Table 12. Peptide-based Drug Industry Opportunities and Challenges Table 13. Peptide-based Drug Industry Restraints Table 14. Global Peptide-based Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Peptide-based Drug Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Peptide-based Drug Market Share by Region (2021-2026) Table 17. Global Peptide-based Drug Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Peptide-based Drug Market Share by Region (2027-2032) Table 19. Global Peptide-based Drug Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Peptide-based Drug Revenue Market Share by Players (2021-2026) Table 21. Global Peptide-based Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Peptide-based Drug Key Players Headquarters & Area Served Table 23. Global Peptide-based Drug Players, Product Type & Application Table 24. Global Peptide-based Drug Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Peptide-based Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Peptide-based Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Peptide-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Peptide-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Peptide-based Drug Revenue Market Share by Type (2021-2026) Table 31. Global Peptide-based Drug Revenue Market Share by Type (2027-2032) Table 32. Global Peptide-based Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Peptide-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Peptide-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Peptide-based Drug Revenue Market Share by Application (2021-2026) Table 36. Global Peptide-based Drug Revenue Market Share by Application (2027-2032) Table 37. Takeda Company Information Table 38. Takeda Business Overview Table 39. Takeda Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Takeda Peptide-based Drug Product Portfolio Table 41. Takeda Recent Development Table 42. Teva Company Information Table 43. Teva Business Overview Table 44. Teva Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Teva Peptide-based Drug Product Portfolio Table 46. Teva Recent Development Table 47. Sanofi Company Information Table 48. Sanofi Business Overview Table 49. Sanofi Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Sanofi Peptide-based Drug Product Portfolio Table 51. Sanofi Recent Development Table 52. J & J Company Information Table 53. J & J Business Overview Table 54. J & J Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. J & J Peptide-based Drug Product Portfolio Table 56. J & J Recent Development Table 57. Novartis Company Information Table 58. Novartis Business Overview Table 59. Novartis Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Novartis Peptide-based Drug Product Portfolio Table 61. Novartis Recent Development Table 62. Merck Company Information Table 63. Merck Business Overview Table 64. Merck Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Merck Peptide-based Drug Product Portfolio Table 66. Merck Recent Development Table 67. Eli Lilly Company Information Table 68. Eli Lilly Business Overview Table 69. Eli Lilly Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Eli Lilly Peptide-based Drug Product Portfolio Table 71. Eli Lilly Recent Development Table 72. AbbVie Company Information Table 73. AbbVie Business Overview Table 74. AbbVie Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. AbbVie Peptide-based Drug Product Portfolio Table 76. AbbVie Recent Development Table 77. AstraZeneca Company Information Table 78. AstraZeneca Business Overview Table 79. AstraZeneca Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. AstraZeneca Peptide-based Drug Product Portfolio Table 81. AstraZeneca Recent Development Table 82. The Medicines Company Information Table 83. The Medicines Business Overview Table 84. The Medicines Peptide-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. The Medicines Peptide-based Drug Product Portfolio Table 86. The Medicines Recent Development Table 87. Novo Nordisk Company Information Table 88. Novo Nordisk Business Overview Table 89. Novo Nordisk Peptide-based Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Novo Nordisk Peptide-based Drug Product Portfolio Table 91. Novo Nordisk Recent Development Table 92. Ipsen Company Information Table 93. Ipsen Business Overview Table 94. Ipsen Peptide-based Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Ipsen Peptide-based Drug Product Portfolio Table 96. Ipsen Recent Development Table 97. Ferring Company Information Table 98. Ferring Business Overview Table 99. Ferring Peptide-based Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Ferring Peptide-based Drug Product Portfolio Table 101. Ferring Recent Development Table 102. North America Peptide-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 103. North America Peptide-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 104. North America Peptide-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 105. North America Peptide-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 106. North America Peptide-based Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. North America Peptide-based Drug Revenue by Country (2021-2026) & (US$ Million) Table 108. North America Peptide-based Drug Revenue by Country (US$ Million) & (2027-2032) Table 109. Europe Peptide-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 110. Europe Peptide-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 111. Europe Peptide-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 112. Europe Peptide-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 113. Europe Peptide-based Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Europe Peptide-based Drug Revenue by Country (2021-2026) & (US$ Million) Table 115. Europe Peptide-based Drug Revenue by Country (US$ Million) & (2027-2032) Table 116. China Peptide-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 117. China Peptide-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 118. China Peptide-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 119. China Peptide-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 120. Asia Peptide-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 121. Asia Peptide-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 122. Asia Peptide-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 123. Asia Peptide-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia Peptide-based Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Asia Peptide-based Drug Revenue by Region (US$ Million) & (2021-2026) Table 126. Asia Peptide-based Drug Revenue by Region (US$ Million) & (2027-2032) Table 127. SAMEA Peptide-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 128. SAMEA Peptide-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 129. SAMEA Peptide-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 130. SAMEA Peptide-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 131. SAMEA Peptide-based Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. SAMEA Peptide-based Drug Revenue by Country (2021-2026) & (US$ Million) Table 133. SAMEA Peptide-based Drug Revenue by Country (US$ Million) & (2027-2032) Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Peptide-based Drug Image Figure 2. Global Peptide-based Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide-based Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Injection Image Figure 5. Oral Image Figure 6. Other Image Figure 7. Global Peptide-based Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Peptide-based Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. Cancer Image Figure 10. Metabolic Disorders Image Figure 11. Central Nervous System Image Figure 12. Other Image Figure 13. Global Peptide-based Drug Market Size (US$ Million) & (2021-2032) Figure 14. Global Peptide-based Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Peptide-based Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Peptide-based Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Peptide-based Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Peptide-based Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Peptide-based Drug Revenue Market Share by Type (2021-2032) Figure 21. Global Peptide-based Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Peptide-based Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Peptide-based Drug Revenue Market Share by Application (2021-2032) Figure 24. North America Peptide-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Peptide-based Drug Revenue Share by Type (2021-2032) Figure 26. North America Peptide-based Drug Revenue Share by Application (2021-2032) Figure 27. North America Peptide-based Drug Revenue Share by Country (2021-2032) Figure 28. United States Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Peptide-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Peptide-based Drug Revenue Share by Type (2021-2032) Figure 33. Europe Peptide-based Drug Revenue Share by Application (2021-2032) Figure 34. Europe Peptide-based Drug Revenue Share by Country (2021-2032) Figure 35. Germany Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Peptide-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Peptide-based Drug Revenue Share by Type (2021-2032) Figure 45. China Peptide-based Drug Revenue Share by Application (2021-2032) Figure 46. Asia Peptide-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Peptide-based Drug Revenue Share by Type (2021-2032) Figure 48. Asia Peptide-based Drug Revenue Share by Application (2021-2032) Figure 49. Asia Peptide-based Drug Revenue Share by Region (2021-2032) Figure 50. Japan Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Peptide-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Peptide-based Drug Revenue Share by Type (2021-2032) Figure 58. SAMEA Peptide-based Drug Revenue Share by Application (2021-2032) Figure 59. SAMEA Peptide-based Drug Revenue Share by Country (2021-2032) Figure 60. Brazil Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Peptide-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
  • Other
Applications
  • Cancer
  • Metabolic Disorders
  • Central Nervous System
  • Other
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • J & J
  • Novartis
  • Merck
  • Eli Lilly
  • AbbVie
  • AstraZeneca
  • The Medicines
  • Novo Nordisk
  • Ipsen
  • Ferring

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peptide-based Drug Market by Type
  3. 1.2.1 Global Peptide-based Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Injection
  5. 1.2.3 Oral
  6. 1.2.4 Other
  7. 1.3 Peptide-based Drug Market by Application
  8. 1.3.1 Global Peptide-based Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Cancer
  10. 1.3.3 Metabolic Disorders
  11. 1.3.4 Central Nervous System
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Peptide-based Drug Market Dynamics
  1. 2.1 Peptide-based Drug Industry Trends
  2. 2.2 Peptide-based Drug Industry Drivers
  3. 2.3 Peptide-based Drug Industry Opportunities and Challenges
  4. 2.4 Peptide-based Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Peptide-based Drug Market Perspective (2021-2032)
  2. 3.2 Global Peptide-based Drug Growth Trends by Region
  3. 3.2.1 Global Peptide-based Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peptide-based Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Peptide-based Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Peptide-based Drug Revenue by Players
  2. 4.1.1 Global Peptide-based Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Peptide-based Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Peptide-based Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peptide-based Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Peptide-based Drug Key Players Headquarters & Area Served
  7. 4.4 Global Peptide-based Drug Players, Product Type & Application
  8. 4.5 Global Peptide-based Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Peptide-based Drug Market CR5 and HHI
  11. 4.6.3 2025 Peptide-based Drug Tier 1, Tier 2, and Tier 3
5 Peptide-based Drug Market Size by Type
  1. 5.1 Global Peptide-based Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Peptide-based Drug Revenue by Type (2021-2032)
  3. 5.3 Global Peptide-based Drug Revenue Market Share by Type (2021-2032)
6 Peptide-based Drug Market Size by Application
  1. 6.1 Global Peptide-based Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Peptide-based Drug Revenue by Application (2021-2032)
  3. 6.3 Global Peptide-based Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Peptide-based Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Peptide-based Drug Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Peptide-based Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Peptide-based Drug Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Peptide-based Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Peptide-based Drug Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 J & J
  20. 7.4.1 J & J Company Information
  21. 7.4.2 J & J Business Overview
  22. 7.4.3 J & J Peptide-based Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 J & J Peptide-based Drug Product Portfolio
  24. 7.4.5 J & J Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Peptide-based Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Peptide-based Drug Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 Merck
  32. 7.6.1 Merck Company Information
  33. 7.6.2 Merck Business Overview
  34. 7.6.3 Merck Peptide-based Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Merck Peptide-based Drug Product Portfolio
  36. 7.6.5 Merck Recent Developments
  37. 7.7 Eli Lilly
  38. 7.7.1 Eli Lilly Company Information
  39. 7.7.2 Eli Lilly Business Overview
  40. 7.7.3 Eli Lilly Peptide-based Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Eli Lilly Peptide-based Drug Product Portfolio
  42. 7.7.5 Eli Lilly Recent Developments
  43. 7.8 AbbVie
  44. 7.8.1 AbbVie Company Information
  45. 7.8.2 AbbVie Business Overview
  46. 7.8.3 AbbVie Peptide-based Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 AbbVie Peptide-based Drug Product Portfolio
  48. 7.8.5 AbbVie Recent Developments
  49. 7.9 AstraZeneca
  50. 7.9.1 AstraZeneca Company Information
  51. 7.9.2 AstraZeneca Business Overview
  52. 7.9.3 AstraZeneca Peptide-based Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 AstraZeneca Peptide-based Drug Product Portfolio
  54. 7.9.5 AstraZeneca Recent Developments
  55. 7.10 The Medicines
  56. 7.10.1 The Medicines Company Information
  57. 7.10.2 The Medicines Business Overview
  58. 7.10.3 The Medicines Peptide-based Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 The Medicines Peptide-based Drug Product Portfolio
  60. 7.10.5 The Medicines Recent Developments
  61. 7.11 Novo Nordisk
  62. 7.11.1 Novo Nordisk Company Information
  63. 7.11.2 Novo Nordisk Business Overview
  64. 7.11.3 Novo Nordisk Peptide-based Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Novo Nordisk Peptide-based Drug Product Portfolio
  66. 7.11.5 Novo Nordisk Recent Developments
  67. 7.12 Ipsen
  68. 7.12.1 Ipsen Company Information
  69. 7.12.2 Ipsen Business Overview
  70. 7.12.3 Ipsen Peptide-based Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Ipsen Peptide-based Drug Product Portfolio
  72. 7.12.5 Ipsen Recent Developments
  73. 7.13 Ferring
  74. 7.13.1 Ferring Company Information
  75. 7.13.2 Ferring Business Overview
  76. 7.13.3 Ferring Peptide-based Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Ferring Peptide-based Drug Product Portfolio
  78. 7.13.5 Ferring Recent Developments
8 North America
  1. 8.1 North America Peptide-based Drug Revenue (2021-2032)
  2. 8.2 North America Peptide-based Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Peptide-based Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Peptide-based Drug Revenue by Type (2027-2032)
  5. 8.3 North America Peptide-based Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Peptide-based Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Peptide-based Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Peptide-based Drug Revenue by Application (2027-2032)
  9. 8.5 North America Peptide-based Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Peptide-based Drug Revenue by Country
  11. 8.6.1 North America Peptide-based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Peptide-based Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Peptide-based Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Peptide-based Drug Revenue (2021-2032)
  2. 9.2 Europe Peptide-based Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Peptide-based Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Peptide-based Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Peptide-based Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Peptide-based Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Peptide-based Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Peptide-based Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Peptide-based Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Peptide-based Drug Revenue by Country
  11. 9.6.1 Europe Peptide-based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Peptide-based Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Peptide-based Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Peptide-based Drug Revenue (2021-2032)
  2. 10.2 China Peptide-based Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Peptide-based Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Peptide-based Drug Revenue by Type (2027-2032)
  5. 10.3 China Peptide-based Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Peptide-based Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Peptide-based Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Peptide-based Drug Revenue by Application (2027-2032)
  9. 10.5 China Peptide-based Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peptide-based Drug Revenue (2021-2032)
  2. 11.2 Asia Peptide-based Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Peptide-based Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Peptide-based Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Peptide-based Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Peptide-based Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Peptide-based Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Peptide-based Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Peptide-based Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Peptide-based Drug Revenue by Country
  11. 11.6.1 Asia Peptide-based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Peptide-based Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Peptide-based Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peptide-based Drug Revenue (2021-2032)
  2. 12.2 SAMEA Peptide-based Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Peptide-based Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Peptide-based Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Peptide-based Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Peptide-based Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Peptide-based Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Peptide-based Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Peptide-based Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Peptide-based Drug Revenue by Country
  11. 12.6.1 SAMEA Peptide-based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Peptide-based Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Peptide-based Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst